Companies › Biojiva
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Ophthalmology; next expected readout Apr 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Botulinum Toxin Type A (RT001) Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 2 | Infantile Neuroaxonal Dystrophy | – |
| BRX011 | – | Phase 1 | Geographic Atrophy | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03570931 | Botulinum Toxin Type A (RT001) | Phase 2 | Infantile Neuroaxonal Dystrophy | Metabolic and endocrine | Aug 2020 |
| NCT07029945 | BRX011 | Phase 1 | Geographic Atrophy | Ophthalmology | Apr 2029 |
AbbVie Merz Therapeutics Ipsen Huons Biopharma Merz Aesthetics Merz Pharmaceuticals Merz North America
Nacuity Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Sling Therapeutics Aptabio Therapeutics PolyActiva
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.